17:10 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Hyperoxaluria Mouse studies suggest CRISPR-Cas9-based gene editing therapies targeting HAO1 could help treat primary hyperoxaluria type 1, which is caused by loss-of-function AGXT mutations and results in renal accumulation of glyoxalate and oxalate. The...
16:15 , Apr 27, 2018 |  BC Week In Review  |  Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) said on April 20 it has resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing. In 2015, Alnylam filed a suit...
23:19 , Apr 20, 2018 |  Company News  |  Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.82 (18%) to $12.01 Friday after the company said it had resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing....
18:09 , Mar 16, 2018 |  BC Week In Review  |  Company News

Sanofi declines option for Alnylam's lumasiran

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain development and commercialization rights to lumasiran (ALN-GO1) outside the U.S., Canada and Western Europe....
21:11 , Mar 12, 2018 |  BC Extra  |  Company News

Sanofi declines option for Alnylam's lumasiran

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain development and commercialization rights to lumasiran (ALN-GO1) outside the U.S., Canada and Western Europe....
19:51 , Aug 18, 2017 |  BC Week In Review  |  Company News

Dicerna sues Alnylam for alleging misappropriation of trade secrets

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) filed a suit in the U.S. District Court for the District of Massachusetts alleging that Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is using “sham litigation” to “thwart Dicerna’s competitive business activities and illegally...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

ALN-GO1: Interim Phase I/II data

Interim data from 32 healthy volunteers in Part A of a single-blind, placebo-controlled, dose-escalation, U.K. Phase I/II trial showed that single doses of 0.3, 1, 3 and 6 mg/kg subcutaneous ALN-GO1 were generally well tolerated...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Clinical News

ALN-GO1: Phase I/II started

Alnylam began a single-blind, placebo-controlled, dose-escalation, U.K. Phase I/II trial of subcutaneous ALN-GO1 in up to 40 healthy volunteers and up to 20 patients. Volunteers will receive single doses of ALN-GO1 and patients will receive...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Alnylam preclinical data

In a rat model of PH1, once-weekly subcutaneous ALN-GO1 reduced mean urinary oxalate levels by up to 98%. Additionally, ALN-GO1 produced up to 99% silencing of glycolate oxidase mRNA in non-human primates. Data were presented...